Evaluating patient experience and healthcare utilisation in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

被引:0
|
作者
Siu, Adrian [1 ,2 ]
Steffens, Daniel [1 ,2 ]
Ansari, Nabila [1 ,3 ]
Karunaratne, Sascha [1 ,2 ]
Solanki, Henna [1 ]
Ahmadi, Nima [1 ,3 ]
Solomon, Michael [1 ,2 ,3 ]
Koh, Cherry [1 ,2 ,3 ]
机构
[1] CO Royal Prince Alfred Hosp, Surg Outcomes Res Ctr SOuRCe, POB M157,Missenden Rd, Camperdown, NSW 2050, Australia
[2] Univ Sydney, Fac Med & Hlth, Cent Clin Sch, Sydney, NSW, Australia
[3] Royal Prince Alfred Hosp, Dept Colorectal Surg, Sydney, NSW, Australia
关键词
cytoreductive surgery; geographic disparity; healthcare equity; healthcare utilisation; hyperthermic intraperitoneal chemotherapy; patient experience; peritoneal malignancies; surgical oncology; HIPEC;
D O I
10.1071/AH24192
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective. Approximately 30% of Australians reside in rural communities, where accessing healthcare facilities can be challenging due to considerable distance. This can result in disparities in healthcare equity, subsequently increasing risk of adverse health outcomes, delayed diagnosis, and diminished quality of life. These geographical constraints may be exacerbated in advanced cancers for which treatment is available only at selected centres with appropriate expertise. The aim of this study was therefore to explore the impact of patient residence on experience and healthcare utilisation following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Methods. A retrospective study examined consecutive CRS and HIPEC patients at Royal Prince Alfred hospital from 2017 to 2022. Patients were stratified as metropolitan and regional based on their postcode. Demographics, experiential, and healthcare utilisation data were collected at multiple time points. Statistical analysis included chi-squared and T-tests. Results. Of the 317 participants, 228 (72%) were from metropolitan and 89 (28%) from regional areas. Regional patients tended to rate their hospital experience as 'very good' (P = 0.016). Metropolitan patients were more compliant with surgical follow-up (P < 0.001). No other differences were observed in patient characteristics, experience or healthcare utilisation. Conclusions. The geographical location of patients undergoing CRS and HIPEC for peritoneal malignancies at a major tertiary referral centre did not significantly influence their experience or healthcare utilisation outcomes. Future studies should evaluate long-term healthcare service utilisation or the ramifications of reduced follow-up on recurrence and survival, which will contribute to a deeper understanding of resource allocation in metropolitan and regional Australia, and illuminate its impact on clinical outcomes.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Durnford, S.
    Boss, L.
    Bell, J.
    BJA EDUCATION, 2021, 21 (05) : 187 - 193
  • [2] Reply to: Initial experience with hyperthermic intraperitoneal chemotherapy and cytoreductive surgery
    Macri, A.
    Fleres, F.
    Cucinotta, E.
    Saladino, E.
    INDIAN JOURNAL OF CANCER, 2014, 51 (04) : 437 - 437
  • [3] Techniques for Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
    Rebecca M. Dodson
    Michael Kuncewitch
    Konstantinos I. Votanopoulos
    Perry Shen
    Edward A. Levine
    Annals of Surgical Oncology, 2018, 25 : 2152 - 2158
  • [4] Techniques for Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
    Dodson, Rebecca M.
    Kuncewitch, Michael
    Votanopoulos, Konstantinos I.
    Shen, Perry
    Levine, Edward A.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (08) : 2152 - 2158
  • [5] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for ovarian cancer: World experience
    Helm, C. William
    Intraperitoneal Cancer Therapy, 2007, : 147 - 161
  • [6] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience
    Iversen, L. H.
    Rasmussen, P. C.
    Hagemann-Madsen, R.
    Laurberg, S.
    COLORECTAL DISEASE, 2013, 15 (07) : E365 - E372
  • [7] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for ovarian cancer: Experience in France
    Glehen, Olivier
    Gilly, Francois-Noel
    INTRAPERITONEAL CANCER THERAPY, 2007, : 131 - +
  • [8] Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer
    Philipp Horvath
    Ingmar Königsrainer
    memo - Magazine of European Medical Oncology, 2020, 13 : 426 - 429
  • [9] Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer
    Horvath, Philipp
    Koenigsrainer, Ingmar
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2020, 13 (04) : 426 - 429
  • [10] Experience after 100 patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Koenigsrainer, Ingmar
    Zieker, Derek
    Glatzle, Joerg
    Lauk, Olivia
    Klimek, Julia
    Symons, Stephan
    Bruecher, Bjoern
    Beckert, Stefan
    Koenigsrainer, Alfred
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (17) : 2061 - 2066